Story · Medicine & Biotech
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
3 outlets · first reported by BioPharma Dive on · latest · 3 countries
Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms. (BioPharma Dive)
Coverage, in order
-
Lilly adds to buyout streak with $1.5B purchase of startup CalytrixLilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
-
Lilly buys Calytrix Bio for $1.5 billionΗ Lilly αγοράζει την Calytrix Bio για και 1,5 δισεκατομμύριο δολάρια
The deal is expected to strengthen Lilly's presence in the field.Η συμφωνία αναμένεται να ενισχύσει την παρουσία της Lilly στην αιματολογία.
-
Lilly strikes again, buying Calytrix in $1.5bn deal
Lilly strikes again, buying Calytrix in $1.5bn deal Phil.Taylor Mon, 16/11/2026 - 13:35
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.